# Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)

> **NCT04184063** · PHASE2 · COMPLETED · sponsor: **EmeraMed** · enrollment: 20 (actual)

## Conditions studied

- Progressive Supranuclear Palsy
- Multiple System Atrophy

## Interventions

- **DRUG:** NBMI
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04184063
- **Lead sponsor:** EmeraMed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-16
- **Primary completion:** 2020-07-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04184063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04184063, "Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04184063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*